Thursday February 19, 05:31 PM
Genentech working to minimize Raptiva risks
WASHINGTON, Feb 19 (Reuters) - Genentech Inc (NYSE: DNA - news) is developing plans to minimize the risks of a deadly infection reported in patients who took the company's Raptiva psoriasis drug, a company spokeswoman said on Thursday.
The European Medicines Agency recommended suspension of Raptiva's marketing approval after three confirmed reports of progressive multifocal leukoencephalopathy, or PML. U.S. regulators said they were reviewing the cases.
'We are evaluating all possible approaches to address the risk of PML with Raptiva use, including a risk minimization plan,' Genentech spokeswoman Tara Cooper said.
Genentech markets Raptiva in the United States. Merck Serono (Virt-X: SEO.VX - news) , a unit of Merck KGaA (MKGAY.PK - news) , holds marketing rights to Raptiva in Europe.
(Reporting by Lisa Richwine, editing by Lisa Von Ahn) Keywords: GENENTECH RAPTIVA/RISKS
|
|
|
Send Article by Email
Send Article by IM
Blog This with Y! 360
Printable View
